Merck & Co., Inc. (MRK)
NYSE: MRK · Real-Time Price · USD
152.55
+3.56 (2.39%)
At close: Aug 21, 2026, 4:00 PM EDT
153.49
+0.94 (0.62%)
After-hours: Aug 21, 2026, 7:59 PM EDT
Merck & Co. Revenue
Merck & Co. had revenue of $16.61B in the quarter ending June 30, 2026, with 5.07% growth. This brings the company's revenue in the last twelve months to $66.57B, up 4.64% year-over-year. In the year 2025, Merck & Co. had annual revenue of $65.01B with 1.31% growth.
Revenue (ttm)
$66.57B
Revenue Growth
+4.64%
P/S Ratio
5.65
Revenue / Employee
$887,587
Employees
75,000
Market Cap
376.37B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 65.01B | 843.00M | 1.31% |
| Dec 31, 2024 | 64.17B | 4.05B | 6.74% |
| Dec 31, 2023 | 60.12B | 832.00M | 1.40% |
| Dec 31, 2022 | 59.28B | 10.58B | 21.72% |
| Dec 31, 2021 | 48.70B | 7.19B | 17.31% |
| Dec 31, 2020 | 41.52B | 2.40B | 6.13% |
| Dec 31, 2019 | 39.12B | -3.17B | -7.50% |
| Dec 31, 2018 | 42.29B | 2.17B | 5.41% |
| Dec 31, 2017 | 40.12B | 315.00M | 0.79% |
| Dec 31, 2016 | 39.81B | 309.00M | 0.78% |
| Dec 31, 2015 | 39.50B | -2.74B | -6.48% |
| Dec 31, 2014 | 42.24B | -1.80B | -4.08% |
| Dec 31, 2013 | 44.03B | -3.23B | -6.84% |
| Dec 31, 2012 | 47.27B | -780.00M | -1.62% |
| Dec 31, 2011 | 48.05B | 2.06B | 4.48% |
| Dec 31, 2010 | 45.99B | 18.56B | 67.66% |
| Dec 31, 2009 | 27.43B | 3.58B | 15.00% |
| Dec 31, 2008 | 23.85B | -347.70M | -1.44% |
| Dec 31, 2007 | 24.20B | 13.60B | 128.41% |
| Dec 31, 2006 | 10.59B | 1.09B | 11.42% |
| Dec 31, 2005 | 9.51B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Johnson & Johnson | 97.93B |
| Eli Lilly and Company | 79.67B |
| AbbVie | 64.39B |
| Pfizer | 63.70B |
| AstraZeneca | 61.37B |
| Novartis AG | 56.69B |
| Sanofi | 55.89B |
| Novo Nordisk | 50.34B |
MRK News
- 19 hours ago - Why Is Merck Stock Still An Undervalued Mega-Cap In Pharma? - Forbes
- 1 day ago - Merck price target raised to $160 from $140 at Goldman Sachs - TheFly
- 1 day ago - Merck Stock (MRK) Is a Strong Buy as 3 Top Wall Street Analysts Hike Price Targets - TipRanks
- 1 day ago - Moderna is paring back gains, but Merck stock remains a buy - Invezz
- 1 day ago - Moderna Stock Rockets Higher After Positive Cancer Vaccine Trial Data - Investopedia
- 1 day ago - Merck price target raised to $170 from $142 at BMO Capital - TheFly
- 2 days ago - Moderna Stock (MRNA) Forecast: BofA Upgrades Rating on Cancer Vaccine Update, Goldman Raises Price Target - TipRanks
- 2 days ago - Merck price target raised to $175 from $145 at UBS - TheFly